Abstract: A method for determining wavefront shapes of a multi-spectral signal light beam from a single signal image acquisition of said multi-spectral signal beam, with a device including an optical assembly made at least of an optical mask and an imaging sensor, notably a matrix imaging sensor, for generating and recording intensity patterns of incident beams, by having these beams reflect on, or propagate through, the optical mask. The optical mask having the optical properties: i) to cause the intensity pattern to depend on the wavefront shape, so that a tilt applied to the wavefront shape results in a displacement amount of the intensity pattern, and ii) to produce uncorrelated intensity patterns over at least one surface area A of the imaging sensor, for a plurality of respective incident monochrome beams of different wavelengths having a same wavefront shape.

Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.

Abstract: A method for depositing an object, including: —approaching, in an enclosure, a holder in the direction of a carrier substrate, then—transferring, in the enclosure, the object from the holder to an area for depositing the carrier substrate. The transfer step is preferably carried out when the inside of the enclosure is in a vacuum at a pressure below 10?6 bar.

Abstract: A method for manufacturing a superconducting LC-type resonator of the type including at least one high-resistivity substrate on which are printed an inductive meander, a first so-called lower electrode and a second so-called upper electrode arranged opposite the first so as to form together a capacitor connected in parallel with the inductive meander, as well as inductive coupling means dedicated to the resonator, in which a sacrificial aluminium layer is deposited between the first and second electrodes. Also disclosed is the superconducting LC-type resonator thus obtained and the use of such a resonator for detecting the noise of a millimetre photon.

Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: A calibration standard for determining an intensity decay related to an evanescent field generated close to the interface between a sample to be tested and a substrate on which the sample is to be deposited, preparation and analysis methods and use thereof.

Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

Abstract: A method for determining wavefront shapes of N angular channels CL of different propagation directions PL, said propagation directions PL being determined by a mean propagation direction vector , from a single signal image acquisition I(x,y) of a multi-angular signal light beam containing said angular channels, each angular channel Ci being separated from other angular channels Cj by an angular separation ??ij defined by ??ij=arccos, where “·” stands for the inner product between and .

Abstract: The present application relates to a double-stranded DNA molecule comprising a first double-stranded DNA molecule (1) connected to a second double-stranded DNA molecule (2) by at least one covalent bond which is not a phosphodiester, phosphorothioate, phosphoramidate or phosphorodiamidate bond, preferably by a tether, said tether preferably being a double-stranded DNA molecule.

Abstract: The present invention relates to a novel use of total cellular iron, preferably under the form of ferrous iron (Fe2+), as a marker of cancer stem cells (CSCs). The invention also relates to methods using said iron marker, in particular for metastatic cancer diagnosis or treatment, for screening for compounds of interest, as well as for killing CSCs.

Abstract: The present invention relates to a digital multiplex method for detecting and/or quantifying multiple target biomolecules in a sample, said biomolecules being selected from DNA, RNA, and proteins. The present invention further relates to different applications of the digital multiplex method and to a kit.

Abstract: An organic electrochemical transistor, which includes a biologic detection layer and a catalytic layer, the latter being a composite material including noble metal nanoparticles and an organic conductive matrix. Also, a method for detection of a biological analyte wherein a biological fluid is contacted with such an organic electrochemical transistor.

Abstract: The present invention relates to a digital method for detecting and/or quantifying at least one target biomolecules in a sample, said biomolecules being selected from DNA, RNA, and proteins based on isothermal amplification. The present invention further relates to different applications of the digital method and to a kit.

Abstract: A method for determining a health status of a system of interest is proposed. The method comprises acquiring (S1) a time series, extracting (S2) subsequences, selecting (S3) a set of subsequences, classifying (S4) the subsequences of the set into several groups on the basis of at least one criterion of resemblance to at least one reference subsequence, and constructing (S5) a normal operating model of the system of interest. The construction includes, for each group, a modeling (S51) of a representative subsequence and a determination (S52) of an associated weight. The normal model is defined by the modeled subsequences and the associated weights. The method further includes an attribution (S6) of a normality score to each subsequence extracted by comparison with the normal model, an identification (S7) of at least one abnormal subsequence, and a determination (S8) of the health status of the system of interest.

Abstract: The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).

Abstract: The invention concerns a method determining an optimum drug dosing regimen to treat a patient efficiently against drug-sensitive pathogenic agents. From relevant patient-related data and the drug concentration measured at a random time in the patients body, the method estimates the drug concentration time-course based on a Bayesian model. The residual concentration (Cr) and an efficiency pharmacokinetic parameter (PPE) adapted to said drug and patient are computed from the estimated concentration. A dosing regimen is then determined by comparing the PPE to an efficiency target (CE) for efficiency purposes. The method further may further take into account toxicity constraints by comparing the residual drug concentration (Cr) to at least a toxic concentration (Ctox). A concentration of said drug is determined (E13) based on the result the above comparisons to provide a proposed dose for said optimum dosing regimen.

Abstract: The invention relates to a method for acquiring an image by an imager (20) comprising a matrix of pixels configured to generate an electric response when exposed to an incident light flux travelling through an optical path (21) in which is arranged a wavefront correction element (22), comprising the following steps: 1) initiating the exposure of the pixels to the incident light flux; 2) for a plurality of iterations during the exposure: 2.1) non-destructive reading of the electric responses of pixels of a region of interest; 2.2) determining an evolution of the spatial distribution of pixels in logarithmic mode previous iteration with respect to the previous iteration; 2.3) based on said evolution, establishing a command for the wavefront correction element (22) in order to correct the wavefront; 2.4) configuring the wavefront correction element, 3) reading the electric responses of the pixels resulting in an image.

Abstract: Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. The aimed of the inventors was to characterize the natural history of AAV infection in the liver. Viral DNA was thus quantified in tumor and non-tumor liver tissues of 1461 patients. Presence of episomal form and viral mRNA expression were analyzed using a DNAse/TaqMan based assay and quantitative RT-PCR. In silico analyses using viral capture data explored viral variants and new clonal insertions. AAV DNA was detected in 21% of the patients equally distributed in 2 major viral subtypes: one similar to AAV2, the other hybrid between AAV2 and AAV13 sequences. Thus the inventors provided an integrated analysis of the wild type AAV infection in the liver with the identification of viral genotypes, molecular forms, helper virus relationship and viral integrations.

Abstract: A method for providing cardioprotection in a subject who experienced a myocardial infarction, including administering a therapeutically effective amount of a Granzyme B inhibitor. Following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in ischemic heart tissue, and release Granzyme B, leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is produced by other cell types (e.g., NK cells). Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI.